Phase 4
N=1,250
Jet Injection for Influenza
Influenza, Human
Bottom Line
View on ClinicalTrials.gov: NCT01688921 ↗Enrolled (actual)
1,250
Serious AEs
0.2%
Results posted
Oct 2014
Primary outcome: Primary: Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) — 4.43; 4.38; 5.64; 5.64 Titers
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- AFLURIA vaccine (2012-2013 formulation) (Biological); Needle-Syringe (Device); Stratis needle-free injection device (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- PharmaJet, Inc.
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) |
4.43; 4.38; 5.64; 5.64 | — |
| PRIMARY Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) |
4.22; 4.32; 5.51; 5.58 | — |
| PRIMARY Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT) |
2.60; 2.54; 3.75; 3.68 | — |
| PRIMARY Anti Influenza Type A/H1N1 Seroconversion |
37.5; 38.4 | — |
| PRIMARY Anti Influenza Type A/H3N2 Seroconversion |
43.8; 45.1 | — |
| PRIMARY Anti Influenza Type B Seroconversion |
34.9; 35.2 | — |
| SECONDARY Number of Subjects With Complaints Within 30 Minutes Following Vaccination |
163; 69; 104; 36; 63; 17 | <0.001 sig |
| SECONDARY Number of Subjects With Vaccine Reactogenicity Events |
397; 299; 551; 472; 151; 50 | <0.001 sig |
| SECONDARY Number of Subjects With Spontaneously Reported Adverse Events |
92; 73 | — |
| SECONDARY Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again |
89 | — |
Summary
The purpose of this study is to determine if the administration of a seasonal flu vaccine using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and syringe administration, as measured by laboratory tests of immune response.
Eligibility Criteria
Inclusion Criteria
- Adults aged ≥18 and ≤64 years of age at the time of enrollment
- Willing and able to give informed consent after reading the consent form and adequate opportunity to discuss the study with the investigator or qualified designee
- Willing and able to adhere to all protocol required study procedures and to attend scheduled visits.
- Able to receive the TIV influenza vaccine, based on University of Colorado Health (UCH) employee health flu screening guidelines.
- Stable health status with no exclusionary medical or neuropsychiatric conditions as determined during the screening evaluation and based on the clinical judgment of the investigator or qualified designee.
- Access to a consistent means of telephone contact
Exclusion Criteria
- Presence of any febrile illness (oral temperature >38°C) on the day of immunization. Such subjects will be reevaluated for enrollment after resolution of illness.
- Presence of significant acute or chronic uncontrolled medical or neuropsychiatric illness and /or presence of any significant condition that may prohibit inclusion as determined by the investigator or his qualified designee. Uncontrolled is defined as: requiring institution of a new treatment within 1 month prior to study enrollment or change in medication dosage in the month prior to study enrollment.
- Any immunosuppressive condition including: history of HIV infection, cancer or cancer treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more days in total) within 1 month of study enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study enrollment. Any significant disorder of coagulation that would increase the risk of intramuscular injections or treatment with Coumadin derivatives or heparin.
- Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza vaccine.
- History of severe or previous serious adverse reaction after an influenza vaccination.
- Receipt of any immunoglobulin and/or blood products within 3 months of immunization or planned administration of any of these products during the study period.
- Prior history of any demyelinating disease including Guillain-Barre syndrome.
- Presence of an active neurological disorder.
- History of significant alcohol or drug abuse within one year prior to study enrollment.
- Influenza vaccination or laboratory confirmed influenza infection within the previous six months before study vaccination or planned influenza vaccination during the study period.
- Planned administration of any non-influenza vaccines 30 days prior to the study or during the study period.
- Pregnant or plans to become pregnant during the study period.
- Currently enrolled in another vaccine or drug study.
Data sourced from ClinicalTrials.gov (NCT01688921). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.